No retraction, correction or concern found when last checked on Oct 17, 2026.

Factors affecting the composition of the gut microbiota, and its modulation

Nihal Hasan, Hongyi Yang

PeerJ · 2019

Abstract

Gut microbiota have important functions in the body, and imbalances in the composition and diversity of those microbiota can cause several diseases. The host fosters favorable microbiota by releasing specific factors, such as microRNAs, and nonspecific factors, such as antimicrobial peptides, mucus and immunoglobulin A that encourage the growth of specific types of bacteria and inhibit the growth of others. Diet, antibiotics, and age can change gut microbiota, and many studies have shown the relationship between disorders of the microbiota and several diseases and reported some ways to modulate that balance. In this review, we highlight how the host shapes its gut microbiota via specific and nonspecific factors, how environmental and nutritional factors affect it, and how to modulate it using prebiotics, probiotics, and fecal microbiota transplantation.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1The human intestines are inhabited by complex microbial communities called gut microbiota, and the number of these microbes has been estimated to exceed 1014. Studies on humans and animal models have reported the role of gut microbiota in human health. The gut microbiota have many important functions in body, including supporting resistance to pathogens, affecting the immune system, playing a role in digestion and metabolism, controlling epithelial cell proliferation and differentiation, modifying insulin resistance and affecting its secretion, and affecting the behavioral and neurological functions of the host.

2Studies have shown that transplantation of gut microbiota of the conventional zebrafish to germ-free mice and conventional mouse gut to germ-free zebrafish resulted the gut microbiota of both receivers after transplantation resembled the microbiota of their conventional species. It indicates that there are specific mechanisms used by the host to shape its own gastrointestinal microbiota and maintain its homeostasis. There are several factors that can change gut microbiota, including host genetic, diet, age, mode of birth and antibiotics (Fig. 1A). The perturbation of the gut microbiota population associated with several human diseases that include inflammatory bowel diseases (IBD), obesity and diabetes, allergy, autoimmune diseases, cardiovascular disease, hypertension, and modulating its composition and diversity is considered a promising treatment for these diseases. There are many ways to modulate gut microbiota, including probiotics, prebiotics, and fecal microbiota transplantation (FMT) (Fig. 1B), which can cause favorable changes in the structure and functions of the gut microbiota and restore it temporarily or permanently. The present review discusses the mechanisms the host uses to shape its gut microbiota and the factors that can modulate these microbes and to improve understanding of the role of FMT, probiotics, and prebiotics in gut community modulation.

Survey methodology

3Literature searching aimed at collecting any published data about cultivation, alteration, and restoration of gut microbiota. We searched literature relevant to the topic of the articles using PubMed and Google Scholar. Key words such as gut microbiota, factors shape gut microbiota, microRNA (miRNA), FMT, probiotics, antibiotic, prebiotics, and antimicrobial peptides (AMPs) were used to search. Then, screened articles were used as references for this review.

Host factors that shape the human microbiota

4Hosts use specific and nonspecific factors to cultivate their own gut microbiota. The host favors the type of microbes that can colonize its intestines and removes other microbes from the body.

Nonspecific host factors

5The host chooses its own gut microbiota by producing several molecular signals that control the structure of the surfaces colonized by microbiota and so influences its composition. These molecules are produced by the intestinal epithelial cells (IEC) and include mucus, AMPs, and immunoglobulin A (IgA), which can encourage the growth of some microbial species and inhibit that of others. In the large intestine, mucus plays an important role in keeping the microbes far from IEC, it is constituted of two layers: the inner layer does not contain any microorganisms whereas the outer layer contains soluble mucins, which are decorated by O-glycans, provide a nutrient source and binding site for gut microbiota. Mucus and mucin O-glycans play a key role in shaping the gut microbiota and selecting the most appropriate microbial species for host health. Utilisation of mucin by gut microbiota is depending on glycoside hydrolases and polysaccharide lyases which are encoded by their genes. Some species of gut microbiota have capacity to degrade complex carbohydrates such as Bacteroides thetaiotaomicron, whose genome contains 260 glycoside hydrolases. While there is not enough mucus in the small intestine, AMPs play an important role in shaping gut microbiota. The gut microbiota by its structural components and metabolites induce AMP production by Paneth cell through a mechanism mediated by pattern recognition receptor (PRR), whereas PRRs are activated by different microbial components, such as flagella and lipopolysaccharide, in a system called microbe-associated molecular patterns (MAMP). PRR-MAMP plays important roles in promoting the function of the mucus barrier and inducing the production of IgA, mucin glycoproteins, and AMPs, and concentration of the AMPs are maximal in small intestinal crypts because of Paneth cells reside at this location. AMPs are secreted by IEC as the body's first line of defense against invaders and these proteins have a broad effect that directly kills bacteria, virus, yeast, fungi, and even cancer cells. These proteins include defensins, cathelicidins, Reg family proteins, and ribonucleases. It has been proven that all dominant species of gut microbiota can resist high concentrations of AMPs, and AMPs may play an important role when the host distinguishes commensal from pathogenic bacteria. Bacteroides, the most abundant Gram-negative genus among the gut microbiota, had resistance to AMPs. After Bacteroides strains lost their ability to produce dephosphorylate lipid A, the sensitivity to AMPs is increased, suggesting that dephosphorylate lipid A gives the Bacteroides their ability to resist the high concentrations of AMPs in the intestine.

6Antibacterial lectins, which can form hexameric pores in Gram-positive bacterial membranes and prevent them from reaching the intestinal mucus layer, are important antibacterial factors that contribute to shaping gut microbiota. On the basis of these secreting factors, IEC promote growth of some bacterial species and inhibit that of others so the host control the shape and structure of its gut microbiota by modulating these secretors.

7In addition, there are plasma cells in the intestinal mucosa that produce secretory immunoglobulin A (SIgA) that can cover the bacteria and control its numbers locally. Further, SIgA plays a role in bacterial biofilm formation by binding to SIgA receptors on bacteria. The presence of gut microbiota was possibly a condition to activate dendritic cells, which induce plasma cells to produce IgA. The absence of IgA can lead to increases in segmental filamentous bacteria, occurs IgA-deficient mice, suggesting that the induced secretory IgA production is a form of competition between different types of gut microbiota.

Specific host factors

8The other host factor that can be used to assess the shape and structure of gut microbiota is miRNAs, which are small non-coding RNAs that are 18–23 nucleotides in length. MiRNAs are generated in the nucleus and then transported to the cytoplasm to effect gene silencing by hybridizing with the 3′ untranslated region of the target gene and promote mRNA degradation or inhibit translation. One miRNA can target different mRNAs, and it has been proven that miRNAs exist outside the cells and circulate in bodily fluids.

9and measured RNA in human stool and demonstrated that miRNAs as potential markers of intestinal malignancy, whereas investigated the gut miRNAs in intestinal contents and feces. All three works demonstrated their ability to affect the composition of the gut microbiota composition. The IEC and Hopx-positive cells are main sources of fecal miRNA. and also investigated the relationship between the deficiency of IEC-miRNA and gut dysbiosis and studied why wild-type fecal transplantation can restore the gut microbiota, indicating that miRNAs were able to regulate the gut microbiome. Several miRNAs can then enter the gut bacterial cells and regulate their growth and gene expression. found that hsa miRNA-515-5P can stimulate Fusobacterium nucleatum growth and that hsa miRNA-1226-5p stimulates E. coli growth via culturing the strains with synthesized mimics miRNA in vitro and affected E. coli in vivo also when given orally to mice. In this way, miRNA was found to have specific effects on gut bacterial growth.

10In addition, demonstrated that miRNA can enter the bacterial cell and settle near bacteria DNA in the nucleus, and then, they studied the effect of synthetic miRNAs on bacterial gene expression and growth. The presence of gut microbiota has an effect on miRNA expression in the intestine. found that nine miRNAs in the colon and ileum had different levels of expression in the germ-free mice which are colonized with pathogen-free mice microbiota. found that microbiota can affect expression of miR-10a, which targets interleukin-12/ interleukin-23p40B, which is itself responsible for innate immune response of the host toward the gut microbiota, suggesting that the gut microbiota can control host innate immune responses by regulating of miRNA expression.

11The gut microbiota can be shaped by administration of fecal miRNAs. The microbiota profile of the recipient becomes similar to that of the donor after transplantation of fecal RNA, as shown in the case of transfer from healthy mouse donors to IEC-deficient mice. This indicates an important potential of application, in the future, diseases related to changes in gut microbiota may be treated using synthetic specific miRNA.

Factors influencing homeostasis of microbiota

12The gut microbiota is established early in life stage but can later be altered by various factors that affect its development and diversity.

Age and delivery pattern

13Microbial intestinal colonization process begins in utero by microbiota in the amniotic fluid and placenta. Studies have reported that there are bacteria and bacterial products, such as DNA, in meconium, amniotic fluid, and the placenta. Studies on the pregnant mice have demonstrated that oral administration of labeled Enterococcus fecium resulted staring isolated it from the newborn stool samples, this result agree with the evidence maternal microbes can be transferred to the amniotic fluid and the placenta. After birth, the mode of delivery affect the early-life development of the gut microbiota. Newborns delivered vaginally have primary gut microbiota dominated by Lactobacillus and Prevotella derived from the mother's vaginal microbiota, while those born via cesarean delivery derive their gut microbiota from the skin, leading to dominance of Streptococcus, Corynebacterium, and Propionibacterium. These primary microbiota evolve over time to become more diverse and relatively stable. At the age 3 years, they become similar to an adult's gut microbiota.

Diet

14After birth, the first effect on the gut microbiota is the infant diet (breast or formula milk). The composition of the milk affect on shaping the early gut microbiota. In breast feeding infants, the species that dominate the gut microbiota are Lactobacillus and Bifidobacterium; breast milk contains oligosaccharides that can be broken down easily by these species, resulting in an increase in short-chain fatty acids, which directs the immune system to increase the expression of immunoglobulin G. Whilst in infants raised on formula, the dominant species are Enterococcus, Enterbacteria, Bacteroides, Clostiridia, and Streptococcus. The primary microbiota acquired during infancy may play an important role in initial immunity during the growth of babies, for this reason, the composition of primary microbiota during this period is very important to protect babies from diseases related to poor immunity. Several studies have compared the gut microbiota population and mucosal immune response between breast and formula feeding and found that the breast feeding caused more stable population and good mucosal immune response.

15Interestingly, human milk microbiota play important roles in immunological activities such as increasing the number of plasma cells in the intestinal environment of newborns that produce IgA, stimulation of cytotoxic Th1 cell, motivation specific cytokines that create a balanced microenvironment, development of local and systemic immune system, and some Lactobacillus strains promote the production of Th1, cytokines and TNF-α, regulate T cell, and stimulate NK cells, CD4+ T-cells and CD8+ T-cells.

16After infancy, the gut microbiota continues its development, and the diet remains key to defining the shape, structure, and diversity of the gut microbiota. Vegetarian diets have been found to be associated with healthy, diverse gut microbiota characterized by the domination of species that can metabolize insoluble carbohydrates, such as Ruminococcus, Roseburia, and Eubacterium, while a non-vegetarian diet (Western diet) has been associated with a decreasing number of Firmicutes and an increase in Bacteroides. Diet can cause important changes even over short periods. After consumption of a Western diet, the gut microbiota ferment amino acids, which result in production of short-chain fatty acids as energy sources, and harmful compounds can be produced. The vegetarian diet inhibits this, and fosters carbohydrate fermentation as the main function of microbiota.

Antibiotics

17The use of antibiotics is a two-edged weapon: it destroys both pathological and beneficial microbes indiscriminately, allowing loss of gut microbiota or the so-called dysbiosis and growth of unwanted microbes. Studies on experimental mice have demonstrated the antibiotics administration affected secondary bile acid and serotonin metabolism in the colon and resulting in delayed intestinal motility by causing microbiota depletion. Antibiotics disrupt the competitive exclusion machinery, a basic property by which microbiota eliminate pathological microbes. This disruption promotes growth of other pathogens, such as Clostridium difficile. Studies have reported that clindamycin, clarithromycin and metronidazole and ciproflaxin affect the microbiota structure for a long time.

18Clindamycin causes changes in microbiota that last 2 years with no recovery in the diversity of Bacteroides. Similarly, the use of clarithromycin in Helicobacter pylori treatment causes a decrease in the population of Actinobacteria, while ciprofloxacin has been shown to cause a decrease in that of Ruminococcus. Vancomycin, which is considered the best treatment option for C. difficile infection (CDI), but, like other antibiotics, it causes changes in gut microbiota that lead to recurrent C. difficile infection (rCDI) or encourage growth of pathological strains of E. coli. Vancomycin treatment also causes depletion of most gut microbiota, such as Bacteroidetes, and it is associated with increases in Proteobacteria species, and decreases in Bacteroidetes, Fuminococcus, and Faecalibacterium. The specific effects of antibiotic administration on the gut microbiota and the recovery time are depending on individual, like effect of the changes in the gut microbiota before treatment.

19In many countries, the antibiotics are used for agriculture particularly intensive farming of poultry and beef, and low doses of antibiotics are routinely given to livestock to increase their growth and weight. Several studies on human and rodent have indicated to an obesogenic impact of antibiotics in humans even in low doses found in food. Pesticides and other chemicals are commonly sprayed on foods and currently, the evidence is lacking for their harm on gut health and the effects of organic food.

Modulation of gut microbiota

20Modulation of the gut microbiota is clinically important to treat all diseases related to imbalances in gut microbiota, and methods for modulating that balance include probiotics, prebiotics, and FMT.

Probiotics

21Probiotics are living microorganisms that, when taken in appropriate doses, protect human health. The most commonly used probiotic species are Lactobacillus, Bifidobacteria and yeasts, such as Saccharomyces boulardii. The proposed mechanisms by which probiotics improve health include promotion of favorable types of gut microbes. In a study by, the administration of a Bifidobacter-supplemented infant formula decreased the intestinal permeability of preterm infants and increased the abundance of fecal Bifidobacterium. Probiotics compete with harmful species for adhesion sites. For example, E. coli Nissle can move and attack pathological microbes and prevent their adhesion. Some probiotics can produce antimicrobial compounds like Lactobacillus reuteri, which produce reuterin that kills harmful microbes directly, and induces immune responses in the host. Bifidobacterium can enhance the function of mucous intestinal barrier, increase serum IgA, and reduce inflammation of the intestine. Bifidobacterium has also been reported to reduce the number of harmful bacteria in stool samples. Several systematic reviews analyzed the role of probiotics on clinical outcomes. The analysis showed substantial evidence for beneficial effects of probiotic supplementation in chronic periodontitis, urinary tract infections, necrotizing enterocolitis, and reduction of total cholesterol and low-density lipoprotein cholesterol. In type 2 diabetes patients, probiotic administration reduced fasting blood glucose and HbA1 and decreased cardiovascular risk. A meta-analysis showed that probiotic therapy for patients with type 2 diabetes significantly decreased insulin concentration and homeostasis model assessment of insulin resistance score, which was an important index to assess insulin resistance in several diseases, such as prediabetes, diabetes mellitus type 2 and metabolic syndrome. reported the efficiency of probiotics in vulvovaginal candidiasis in non-pregnant women indicated that probiotics increased the rate of short term clinical cure and mycological cure and decreased relapse rate at 1 month.

22The utilization of mucins by gut microbiota under dietary fiber deficiency causes the erosion of the colonic mucus barrier and studies on experimental mice demonstrated that administration of Akkermansia muciniphila, mucin degrade, lead to restoration of the gut barrier. A. muciniphila has probiotic properties and can prevent or treat several metabolic disorders. Recently, studies on chow diet-fed mice showed that A. muciniphila supplementation had ability to reduce metabolic inflammation that lead to alleviating body weight gain and reduce fat mass. Moreover, A. muciniphila acts as an energy sensor, its abundance increases with decreasing calories and decreases with extra energy which enables the energy uptake when available.

23Many probiotic products use the microencapsulation technique to protect bacteria from environmental factors, and their effects vary depending on the type and number of bacteria. Generally, the probiotic products contain at least 106–107 CFU. The different doses of probiotics in treating antibiotic-induced diarrhea were compared, indicating that high doses of probiotics were more effective. This is because a large number of the probiotic organisms perish in the stomach before reaching the colon.

24Currently, researchers do not agree on the efficacy of probiotics in intestinal diseases, largely because studies have used different doses and types of probiotics. For example, some studies have shown that probiotics mitigate traveler's diarrhea while others have found them to have no clear benefit.

Prebiotics

25Prebiotics are defined as selective fermentation components that cause specific changes in the activity or structure of gut microbiota and so benefit to the host. Prebiotics usually consist of non-digestible carbohydrates, oligosaccharides, or short polysaccharides like inulin, oligofructose, galactofructose, galacto-oligosaccharides, and xylo-oligosaccharides. Prebiotics must be able to resist gastric acids but yet be degraded by digestive enzymes and become absorbed by the upper tract of the digestive system, fermentation by gut microbiota and inciting the growth or activating useful species of the gut microbiota. Prebiotics affect the microbiota species already present in the colon. The main target species of prebiotics are Lactobacilli and Bifidobacteria and the effects of prebiotics include increasing production of short-chain fatty acids and decreasing pH.

26Dietary fiber consumption is important to maintain intact mucosal barrier function in the gut. Recently, several studies demonstrated the effect of prebiotic fibers on the modulation of the gut microbiota. Studies showed that administration of inulin can prevent the harmful effects of high fat diets on penetrability of the mucus layer and metabolic functions. Evidence indicates that the low fiber Western diet causes weakening in the colonic mucus barrier, that leads to microbiota crept, which results in pathogen susceptibility and inflammation, providing a relationship between the Western diet with chronic diseases. Moreover, the mixture of galacto-oligosaccharides and fructo-oligosaccharides have ability to increasing Bifidobacteria and decreasing Clostridium in the gut whilst galacto-oligosaccharides alone increase Lactobacillus. Additional studies showed that arabino-xylooligosaccharides and inulin alter the intestinal barrier function and immune response.

FMT

27Fecal microbiota transplantation is the process of transplantation of fecal bacteria from healthy donors to patients with intestinal diseases or changes or dysbiosis in natural gut microbiota to restore the community and function of gut microbiota. The first use of FMT took place in China during the 4th century (Fig. 2). Ge Hong reportedly used faeces to treat cases of food poisoning and diarrhea. In the 16th century, Li Shizhen reportedly used fecal matter, later called yellow soup, to treat fever, pain, and several symptoms of intestinal disorders, such as diarrhea, constipation, and vomiting. In modern medicine, Eiseman first reported that FMT has successfully treated many patients with pseudomembranous colitis by enema. In the succeeding years, the use of FMT focused on the treatment of CDI and rCDI with a cure rate of 87–90%. Currently, because of insufficient genetic information that explains the contrast in recipient responses, investigators have studied the donor-dependent effect and suggested the existence of so-called super-donors. In 2015, Moayyedi and colleagues described the super-donor effected on the efficacy of FMT for inducing clinical remission in patients with ulcerative colitis. Whilst and demonstrated that the donor's microbial diversity has an influential role in the therapeutics success of FMT (Fig. 2).

28Fecal microbiota transplantation has a high capacity for treating different diseases, including IBD, irritable bowel syndrome constipation, metabolic diseases, neuropsychiatric conditions, autoimmune diseases, allergic disorders, blood, colon cancer, anti-tumor immunity and chronic fatigue syndrome. Some studies using FMT to treat CDI and IBD are summarized in Table 1. In the most recent studies, reported to eradicate highly drug-resistant enteric bacteria using FMT. While and reported the protective effects of FMT against radiation-induced toxicity in a mouse model. Recently, a non-desirable side effect of the FMT was reported. reported that a patient with chronic radiation colitis developed adhesion ileus 2 days after FMT (Fig. 2).

Transplantation pathway of FMT

29Several pathways (Fig. 3), such as colonoscopy, and enema, have shown pronounced efficiency in FMT. More recently, enteric-coated capsules and capsules containing freeze dried feces or bacteria were also used and the high efficiency of FMT was confirmed.

30Enema is still the easiest, cheapest way of effecting FMT, posing little risk to patients. Recently, colonoscopy has become an attractive option because it can deliver a large volume of fecal matter along the entire colon. However, it is less safe than rectal enemas, posing a greater risk of perforation. Colonoscopy is also more expensive and time-consuming than enema.

31Many recent studies have reported that the stool can be delivered via oral encapsulated FMT or stool enemas. The efficacy of the first dose was about 52–70%, which is lower than that of other methods of administration, such as colonoscopy; but after examination of several rounds of treatment are administered to the patient, the result were similar to those of colonoscopy.

32SER-109, a microbiome therapeutic, is a new kind of therapy composite of commensal bacterial spores. Studies have shown that SER-109 not only relieves dysbiosis but also leads to increases in beneficial bacteria not contained in the product when treating rCDI in patients with a history of multiple relapses. Several studies have also shown that spore-forming organisms isolated from stool sample, could compete metabolically with C. difficile for essential nutrients, and this could prevent CDI. Whilst reported the efficiency of oral delivery of SER-109 to treat rCDI.

33Regardless of the route of FMT, there is enough evidence supporting the conclusion that FMT is a highly efficient, and therapeutic option for several intestinal diseases, characterized by ability to restore the compositions and functions of gut microbiota which are similar to gut microbiota of recipients. Using next-generation sequencing techniques, changes in gut microbiota species could been identified both before and after FMT. An increasing studies have shown that FMT can lead to permanent participation of new species of gut microbiota, such as that found in healthy donor feces, and FMT can increase the number of different bacteria present in recipient feces. Currently, the safety problem of FMT is a main obstacle to use it in more patients because of the complexity of feces microbial community.

Comparison of the efficiency of FMT and probiotics

34Fecal microbiota transplantation has been found to outperform probiotics. Probiotic treatments contain specific bacteria and there is some doubt whether a sufficient quantity survives the stomach acids to reach the gut. To become established in the gut, the probiotic strains must outcompete the resident microbiota and occupy an ecological niche. Because the resident microbiota is inherently resistant to outside colonizer, the probiotic strains may fail to colonize and function in the gut. In addition, probiotics restore microbiota for an interim period. FMT treatment delivered plenty of fecal bacteria to the colon and caused permanent restoration of microbiota. found that FMT administered to the lower intestinal track was more effective with rCDI than delivery to the upper tract. This may be because the growth of many kinds of fecal microbiota is affected by their administration route, for example, Bacteroidetes is sensitive to digestive acids, and the lower tract offers it a gentler environment. Probiotics rarely remain in the colon more than 14 days after the patient ceases taking them, while the effects of FMT on the gut microbiota can persist for 24 weeks, indicating that FMT can cause pronounced changes in the gut microbiota.

Future work

35Several studies have investigated the role of gut microbiota in many diseases, including colorectal cancer, liver disease, and others. In the last few years, gut microbiota has been studied using metagenomic methodologies. reported that the gut microbiome from patients with schizophrenia might be relevant to pathology of schizophrenia via altering neurochemistry and neurologic function. Currently, methods of modulating gut microbiota, including FMT, probiotics, and prebiotics, have come to be considered suitable treatment options for these diseases.

36Future studies of probiotics and prebiotics should focus on the effect on different diseases with an agreement regarding the doses and the kind of bacteria used under each set of pathological conditions. High-throughput technologies allow researchers to easily find answers to many questions surrounding probiotics and prebiotics. This may help us to design new probiotics that more efficient with a higher quality and may lead to find new bacterial strains with probiotics properties.

37Many studies have confirmed the ability of the gut microbiota to modify the expression of the host genes, and the impact of microbiota on miRNA expression was discovered using miRNA arrays, supporting the fact that gut microbiota affects the expression of hundreds of genes in the host. More studies are needed to understand miRNA-microbiota interactions and determine which kinds of microbiota can modulate miRNA expression by combining high-throughput technologies.

38Recently, FMT has been found to be a perfect treatment for rCDI cases that are nonresponsive to antibiotic therapy. Its high efficiency in many diseases has been confirmed, but FMT treatment suffers from a lack of information about the safety of long- and short-term administration. More and safer synthetic bacteria products (e.g., encapsulated formulations and full-spectrum stool-based products) and methods of transplantation need be developed to make FMT easier to use and more acceptable to patients. SER109, the mixture of bacterial spores, has shown high efficiency with rCDI diarrhea, and other similar products are being developed. The synthetic bacteria products may be able to replace traditional fecal treatment. In the future, various bacterial products may contain complicated mixtures of different bacterial species tailored using microbial ecological principles, and doctors may choose the suitable synthetic bacteria mixtures to a specific disease. FMT, probiotics, and other treatments meant to modulate a healthy microbiota may come to be considered suitable alternative treatments to antibiotics for diseases related to imbalances of gut microbiota.

Conclusions

39Maintaining gut microbiota homeostasis is very important to the health. Several factors can directly or indirectly effect on the gut microbiota composition and species abundance. Other factors, different from that mentioned in this review, such as geographical location, maternal lifestyle (urban or rural), and fetal swallowing amniotic fluid, are also probable to contribute to gut microbiota development. The disorder of the gut microbiota is associated with several diseases and manipulating its composition and diversity is important element to control the development of these diseases. Based on data published, it can be concluded that manipulating the gut microbiota, either by prebiotics, probiotics or FMT, seem to be attractive options for the prevention and treatment of disease.

40However, further studies need a full understanding on how manipulating gut microbiota can enhance health. In addition, studies for detecting the missing functions in the gut microbiota during disease will help to select the potential prebiotic, probiotic, or FMT that achieve the desired benefit.

References 230

1.
Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clinical Infectious Diseases. 2003;36(5):580-585.
Not in our library10.1086/367657
2.
Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, Naziri W, Marcuard SP. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics-Proteomics. 2009;6(5):281-295.
Not in our library
3.
Akbari V, Hendijani F. Effects of probiotic supplementation in patients with type 2 diabetes: systematic review and meta-analysis. Nutrition Reviews. 2016;74(12):774-784.
Not in our library10.1093/nutrit/nuw039
4.
Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2012;36(6):503-516.
Not in our library10.1111/j.1365-2036.2012.05220.x
5.
Arkkila PE, Uusitalo-Seppälä R, Lehtola L, Moilanen V, Ristikankare M, Mattila EJ. 29 Fecal bacteriotherapy for recurrent Clostridium difficile infection. Gastroenterology. 2010;138(5):S-5.
Not in our library10.1016/s0016-5085(10)60023-6
6.
Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Downs IA, Zanetti-Yabur A, Ramos Y, Cotto CL, Kassam Z, Elliott RJ, Rosenbaum R, Budree S, Sadovsky RG, Timberlake S, Swanson P, Kim M, Keller MJ. 742-A double-blind, randomized, placebo-controlled trial of fecal microbiota transplantation capsules (FMTC) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Gastroenterology. 2018;154(6):S-154-S-155.
Not in our library10.1016/s0016-5085(18)30932-6
7.
Arpaia N, Campbell C, Fan X, Dikiy S, Van Der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451-455.
Not in our library10.1038/nature12726
8.
Artis D, Wang ML, Keilbaugh SA, He W, Brenes M, Swain GP, Knight PA, Donaldson DD, Lazar MA, Miller HRP, Schad GA, Scott P, Wu GD. RELMβ/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(37):13596-13600.
Not in our library10.1073/pnas.0404034101
9.
Bezirtzoglou E, Tsiotsias A, Welling GW. Microbiota profile in feces of breast-and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe. 2011;17(6):478-482.
Not in our library10.1016/j.anaerobe.2011.03.009
10.
Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therapeutic Advances in Gastroenterology. 2013;6(1):53-68.
Not in our library10.1177/1756283x12454590
11.
Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352(6285):544-545.
Not in our library10.1126/science.aad9358
12.
Borody TJ, Campbell J. Fecal microbiota transplantation: current status and future directions. Expert Review of Gastroenterology & Hepatology. 2011;5(6):653-655.
Not in our library10.1586/egh.11.71
13.
Borody TJ, Campbell J, Torres M, Nowak A, Leis S. Reversal of idiopathic thrombocytopenic purpura [ITP] with fecal microbiota transplantation [FMT]. American Journal of Gastroenterology. 2011;106:S352.
Not in our library
14.
Borody TJ, Nowak A, Finlayson S. The GI microbiome and its role in chronic fatigue syndrome: a summary of bacteriotherapy. Journal of the Australasian College of Nutritional and Environmental Medicine. 2012;31:3.
Not in our library
15.
Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. Journal of Clinical Gastroenterology. 2003;37(1):42-47.
Not in our library10.1097/00004836-200307000-00012
16.
Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. Journal of Clinical Gastroenterology. 2004;38(6):475-483.
Not in our library10.1097/01.mcg.0000128988.13808.dc
17.
Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: first-line treatment for severe Clostridium difficile infection? Journal of Clinical Gastroenterology. 2011;45(8):655-657.
Not in our library10.1097/mcg.0b013e3182257d4f
18.
Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, Van Den Brink MRM, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205-208.
Not in our library10.1038/nature13828
19.
Buffington SA, Di Prisco GV, Auchtung TA, Ajami NJ, Petrosino JF, Costa-Mattioli M. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell. 2016;165(7):1762-1775.
Not in our library10.1016/j.cell.2016.06.001
20.
Buie T. Potential etiologic factors of microbiome disruption in autism. Clinical Therapeutics. 2015;37(5):976-983.
Not in our library10.1016/j.clinthera.2015.04.001
21.
Bunyavanich S, Shen N, Grishin A, Wood R, Burks W, Dawson P, Jones SM, Leung DYM, Sampson H, Sicherer S, Clemente JC. Early-life gut microbiome composition and milk allergy resolution. Journal of Allergy and Clinical Immunology. 2016;138(4):1122-1130.
Not in our library10.1016/j.jaci.2016.03.041
22.
Burns DA, Heap JT, Minton NP. Clostridium difficile spore germination: an update. Research in Microbiology. 2010;161(9):730-734.
Not in our library10.1016/j.resmic.2010.09.007
23.
Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. Journal of Clinical Gastroenterology. 2014;48(8):693-702.
Not in our library10.1097/mcg.0000000000000046
24.
Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, Sanguinetti M, Gasbarrini A. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Alimentary Pharmacology & Therapeutics. 2015;41(9):835-843.
Not in our library10.1111/apt.13144
25.
Carvalho FA, Aitken JD, Vijay-Kumar M, Gewirtz AT. Toll-like receptor-gut microbiota interactions: perturb at your own risk! Annual Review of Physiology. 2012;74(1):177-198.
Not in our library10.1146/annurev-physiol-020911-153330
26.
Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006;313(5790):1126-1130.
Not in our library10.1126/science.1127119
27.
Chevalier C, Stojanović O, Colin DJ, Suarez-Zamorano N, Tarallo V, Veyrat-Durebex C, Rigo D, Fabbiano S, Stevanović A, Hagemann S, Montet X, Seimbille Y, Zamboni N, Hapfelmeier S, Trajkovski M. Gut microbiota orchestrates energy homeostasis during cold. Cell. 2015;163(6):1360-1374.
Not in our library10.1016/j.cell.2015.11.004
28.
Factors Affecting Gastrointestinal Microbiome Development in Neonates · 2018
No notice
29.
Chu DM, Ma J, Prince AL, Antony KM, Seferovic MD, Aagaard KM. Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery. Nature Medicine. 2017;23(3):314-326.
Not in our library10.1038/nm.4272
30.
Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading NC, Villablanca EJ, Wang S, Mora JR, Umesaki Y, Mathis D, Benoist C, Relman DA, Kasper DL. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012;149(7):1578-1593.
Not in our library10.1016/j.cell.2012.04.037
31.
Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: gut microbiota: the neglected endocrine organ. Molecular Endocrinology. 2014;28(8):1221-1238.
Not in our library10.1210/me.2014-1108
32.
Bacterial community structure and functional contributions to emergence of health or necrotizing enterocolitis in preterm infants · 2013
No notice
33.
Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria · 2007
No notice
34.
Cockburn DW, Koropatkin NM. Polysaccharide degradation by the intestinal microbiota and its influence on human health and disease. Journal of Molecular Biology. 2016;428(16):3230-3252.
Not in our library10.1016/j.jmb.2016.06.021
35.
Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid · 2016
No notice
36.
Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, Huot L, Grandjean T, Bressenot A, Delanoye-Crespin A, Gaillot O, Schreiber S, Lemoine Y, Ryffel B, Hot D, Nùñez G, Chen G, Rosenstiel P, Chamaillard M. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. Journal of Clinical Investigation. 2013;123(2):700.
Not in our library10.1172/jci62236
37.
Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis · 2015
No notice
38.
Faecal microbiota transplantation protects against radiation‐induced toxicity · 2017
No notice
39.
Cui L, Zhao T, Hu H, Zhang W, Hua X. Association study of gut flora in coronary heart disease through high-throughput sequencing. BioMed Research International. 2017b;2017:3796359.
Not in our library10.1155/2017/3796359
40.
Cullen TW, Schofield WB, Barry NA, Putnam EE, Rundell EA, Trent MS, Degnan PH, Booth CJ, Yu H, Goodman AL. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science. 2015;347(6218):170-175.
Not in our library10.1126/science.1260580
41.
Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: A Review · 2017
No notice
42.
Microbiota Modulate Host Gene Expression via MicroRNAs · 2011
No notice
43.
Damman C, Brittnacher M, Hayden H, Radey M, Hager K, Miller S, Zisman TL. Su1403 single colonoscopically administered fecal microbiota transplant for ulcerative colitis-a pilot study to determine therapeutic benefit and graft stability. Gastroenterology. 2014;146(5):S-460.
Not in our library10.1016/s0016-5085(14)61646-2
44.
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-563.
Not in our library10.1038/nature12820
45.
Davido B, Batista R, Michelon H, Lepainteur M, Bouchand F, Lepeule R, Salomon J, Vittecoq D, Duran C, Escaut L, Sobhani I, Paul M, Lawrence C, Perronne C, Chast F, Dinh A. Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage? Journal of Hospital Infection. 2017;95(4):433-437.
Not in our library10.1016/j.jhin.2017.02.001
46.
De Palma G, Lynch MDJ, Lu J, Dang VT, Deng Y, Jury J, Umeh G, Miranda PM, Pigrau Pastor M, Sidani S, Pinto-Sanchez MI, Philip V, McLean PG, Hagelsieb M-G, Surette MG, Bergonzelli GE, Verdu EF, Britz-McKibbin P, Neufeld JD, Collins SM, Bercik P. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Science Translational Medicine. 2017;9(379):eaaf6397.
Not in our library10.1126/scitranslmed.aaf6397
47.
De Vrese M, Marteau PR. Probiotics and prebiotics: effects on diarrhea. Journal of Nutrition. 2007;137(3):803S-811S.
Not in our library10.1093/jn/137.3.803s
48.
DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, Van den Brink MRM, Hohmann E, Jenq RR, Chen Y-B. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Advances. 2018;2(7):745-753.
Not in our library10.1182/bloodadvances.2018017731
49.
Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto S, Terrapon N, Muller A, Young VB, Henrissat B, Wilmes P, Stappenbeck TS, Núñez G, Martens EC. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell. 2016;167(5):1339-1353.e21.
Not in our library10.1016/j.cell.2016.10.043
50.
The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing · 2008
No notice
51.
Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proceedings of the National Academy of Sciences of the United States of America. 2010;108:4554-4561.
Not in our library10.1073/pnas.1000087107
52.
Dicksved J, Lindberg M, Rosenquist M, Enroth H, Jansson JK, Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. Journal of Medical Microbiology. 2009;58(4):509-516.
Not in our library10.1099/jmm.0.007302-0
53.
Microbial Prevalence, Diversity and Abundance in Amniotic Fluid During Preterm Labor: A Molecular and Culture-Based Investigation · 2008
No notice
54.
Ding C, Fan W, Gu L, Tian H, Ge X, Gong J, Nie Y, Li N. Outcomes and prognostic factors of fecal microbiota transplantation in patients with slow transit constipation: results from a prospective study with long-term follow-up. Gastroenterology Report. 2017;6(2):101-107.
Not in our library10.1093/gastro/gox036
55.
Dinleyici EC, Eren M, Ozen M, Yargic ZA, Vandenplas Y. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opinion on Biological Therapy. 2012;12(4):395-410.
Not in our library10.1517/14712598.2012.664129
56.
Djuranovic S, Nahvi A, Green R. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science. 2012;336(6078):237-240.
Not in our library10.1126/science.1215691
57.
Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(26):11971-11975.
Not in our library10.1073/pnas.1002601107
58.
Earle KA, Billings G, Sigal M, Lichtman JS, Hansson GC, Elias JE, Amieva MR, Huang KC, Sonnenburg JL. Quantitative imaging of gut microbiota spatial organization. Cell Host & Microbe. 2015;18(4):478-488.
Not in our library10.1016/j.chom.2015.09.002
59.
Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854-859.
Not in our library
60.
Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, De Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences of the Unites States of America. 2013;110(22):9066-9071.
Not in our library10.1073/pnas.1219451110
61.
Friedrich MJ. Genomes of microbes inhabiting the body offer clues to human health and disease. JAMA. 2013;309(14):1447-1449.
Not in our library10.1001/jama.2013.2824
62.
Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. American Journal of Gastroenterology. 2010;105(7):1636-1641.
Not in our library10.1038/ajg.2010.11
63.
Antibiotics-induced depletion of mice microbiota induces changes in host serotonin biosynthesis and intestinal motility · 2017
No notice
64.
Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, Gershovich K, Sabo E, Nevelsky A, Daniel S, Dahan A, Ziv O, Dheer R, Abreu MT, Koren O, Kashi Y, Chowers Y. Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction. Gut. 2018;67(1):97-107.
Not in our library10.1136/gutjnl-2017-313789
65.
Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology. 2017;14(8):491-502.
Not in our library10.1038/nrgastro.2017.75
66.
Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. Journal of Nutrition. 1995;125(6):1401-1412.
Not in our library10.1093/jn/125.6.1401
67.
Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. New England Journal of Medicine. 2000;342(20):1500-1507.
Not in our library10.1056/nejm200005183422007
68.
Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont M, Van Treuren W, Knight R, Bell JT, Spector TD, Clark AG, Ley RE. Human genetics shape the gut microbiome. Cell. 2014;159(4):789-799.
Not in our library10.1016/j.cell.2014.09.053
69.
Goyal A, Yeh A, Bush BR, Firek BA, Siebold LM, Rogers MB, Kufen AD, Morowitz MJ. Safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease. Inflammatory Bowel Diseases. 2018;24(2):410-421.
Not in our library10.1093/ibd/izx035
70.
Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. Journal of Clinical Gastroenterology. 2010;44(8):551-561.
Not in our library10.1097/mcg.0b013e3181e5d06b
71.
Development of the preterm infant gut microbiome: a research priority · 2014
No notice
72.
Grönlund MM, Arvilommi H, Kero P, Lehtonen OP, Isolauri E. Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0-6 months. Archives of Disease in Childhood—Fetal and Neonatal Edition. 2000;83(3):F186-F192.
Not in our library10.1136/fn.83.3.f186
73.
Gross L. Microbes colonize a baby’s gut with distinction. PLOS Biology. 2007;5(7):e191.
Not in our library10.1371/journal.pbio.0050191
74.
Effect of Breast and Formula Feeding on Gut Microbiota Shaping in Newborns · 2012
No notice
75.
Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-2115.
Not in our library10.1136/gutjnl-2018-316434
76.
Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. American Journal of Gastroenterology. 2012;107(5):761-767.
Not in our library10.1038/ajg.2011.482
77.
Harsch IA, Konturek PC. Adhesion ileus after fecal microbiota transplantation in long-standing radiation colitis. Case Reports in Gastrointestinal Medicine. 2019;2019(6):1-4.
Not in our library10.1155/2019/2543808
78.
He Z, Li P, Zhu J, Cui B, Xu L, Xiang J, Zhang T, Long C, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn’s disease complicated with inflammatory mass. Scientific Reports. 2017;7(1):4753.
Not in our library10.1038/s41598-017-04984-z
79.
Hehemann J-H, Correc G, Barbeyron T, Helbert W, Czjzek M, Michel G. Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature. 2010;464(7290):908-912.
Not in our library10.1038/nature08937
80.
Hellemans R, Naegels S, Holvoet J. Fecal transplantation for recurrent Clostridium difficile colitis, an underused treatment modality. Acta Gastro-Enterologica Belgica. 2009;72:269-270.
Not in our library
81.
Hendijani F, Akbari V. Probiotic supplementation for management of cardiovascular risk factors in adults with type II diabetes: a systematic review and meta-analysis. Clinical Nutrition. 2018;37(2):532-541.
Not in our library10.1016/j.clnu.2017.02.015
82.
Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection · 2015
No notice
83.
Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172-184.
Not in our library10.1080/19490976.2017.1290756
84.
Holvoet T, Joossens M, Wang J, Boelens J, Verhasselt B, Laukens D, Van Vlierberghe H, Hindryckx P, De Vos M, De Looze D, Raes J. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2017;66(5):980-982.
Not in our library10.1136/gutjnl-2016-312513
85.
Hooper LV. Do symbiotic bacteria subvert host immunity? Nature Reviews Microbiology. 2009;7(5):367-374.
Not in our library10.1038/nrmicro2114
86.
Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Current Opinion in Rheumatology. 2013;25(4):488-795.
Not in our library10.1097/bor.0b013e32836208de
87.
Houghteling PD, Walker WA. Why is initial bacterial colonization of the intestine important to the infant’s and child’s health? Journal of Pediatric Gastroenterology and Nutrition. 2015;60(3):294-307.
Not in our library10.1097/mpg.0000000000000597
88.
Hu Z, Zhang Y, Li Z, Yu Y, Kang W, Han Y, Geng X, Ge S, Sun Y. Effect of Helicobacter pylori infection on chronic periodontitis by the change of microecology and inflammation. Oncotarget. 2016;7:66700.
Not in our library10.18632/oncotarget.11449
89.
Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterology Clinics of North America. 2006;35(2):355-365.
Not in our library10.1016/j.gtc.2006.03.005
90.
Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine. 2014;93(19):e97.
Not in our library10.1097/md.0000000000000097
91.
Ikram S, Hassan N, Raffat MA, Mirza S, Akram Z. Systematic review and meta-analysis of double-blind, placebo-controlled, randomized clinical trials using probiotics in chronic periodontitis. Journal of Investigative and Clinical Dentistry. 2018;9(3):e12338.
Not in our library10.1111/jicd.12338
92.
Isaac S, Scher JU, Djukovic A, Jiménez N, Littman DR, Abramson SB, Pamer EG, Ubeda C. Short-and long-term effects of oral vancomycin on the human intestinal microbiota. Journal of Antimicrobial Chemotherapy. 2016;72(1):128-136.
Not in our library10.1093/jac/dkw383
93.
Short-Term Antibiotic Treatment Has Differing Long-Term Impacts on the Human Throat and Gut Microbiome · 2010
No notice
94.
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. World Journal of Gastroenterology. 2015;21(29):8787.
Not in our library10.3748/wjg.v21.i29.8787
95.
Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME Journal. 2007;1(1):56-66.
Not in our library10.1038/ismej.2007.3
96.
The gut microbiome in atherosclerotic cardiovascular disease · 2017
No notice
97.
Jiménez E, Marín ML, Martín R, Odriozola JM, Olivares M, Xaus J, Fernández L, Rodríguez JM. Is meconium from healthy newborns actually sterile? Research in Microbiology. 2008;159(3):187-193.
Not in our library10.1016/j.resmic.2007.12.007
98.
Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. The Lancet Gastroenterology & Hepatology. 2018;3(1):17-24.
Not in our library10.1016/s2468-1253(17)30338-2
99.
Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, Mimura I, Morita H, Sugiyama D, Nishikawa H, Hattori M, Hino Y, Ikegawa S, Yamamoto K, Toya T, Doki N, Koizumi K, Honda K, Ohashi K. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016;128(16):2083-2088.
Not in our library10.1182/blood-2016-05-717652
100.
MicroRNAs: new players in IBD · 2014
Corrected
101.
Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study · 2017
No notice
102.
Karlsson F, Tremaroli V, Nielsen J, Backhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes. 2013;62(10):3341-3349.
Not in our library10.2337/db13-0844
103.
Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Archives of Internal Medicine. 2012;172(2):191-193.
Not in our library10.1001/archinte.172.2.191
104.
Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. American Journal of Gastroenterology. 2013;108(4):500-508.
Not in our library10.1038/ajg.2013.59
105.
Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, Bakow B, Curran P, McKenney J, Tisch A, Reinert SE, Machan JT, Brandt LJ. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Annals of Internal Medicine. 2016;165(9):609-616.
Not in our library10.7326/m16-0271
106.
Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. New England Journal of Medicine. 2008;359(18):1932-1940.
Not in our library10.1056/nejmra0707500
107.
Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, Wilson KE, Glover LE, Kominsky DJ, Magnuson A, Weir TL, Ehrentraut SF, Pickel C, Kuhn KA, Lanis JM, Nguyen V, Taylor CT, Colgan SP. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host & Microbe. 2015;17(5):662-671.
Not in our library10.1016/j.chom.2015.03.005
108.
Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, Lombardo M-J, Vulic M, Ohsumi T, Winkler J, Pindar C, McGovern BH, Pomerantz RJ, Aunins JG, Cook DN, Hohmann EL. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. Journal of Infectious Diseases. 2016;214(2):173-181.
Not in our library10.1093/infdis/jiv766
109.
Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. Journal of Clinical Gastroenterology. 2010;44:354-360.
Not in our library10.1097/mcg.0b013e3181c87e02
110.
Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nature Reviews Gastroenterology & Hepatology. 2016;13(9):508-516.
Not in our library10.1038/nrgastro.2016.98
111.
Klingensmith NJ, Coopersmith CM. The gut as the motor of multiple organ dysfunction in critical illness. Critical Care Clinics. 2016;32(2):203-212.
Not in our library10.1016/j.ccc.2015.11.004
112.
Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials · 2016
No notice
113.
The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis · 2017
No notice
114.
Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H, Cloney D, Kugathasan S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. Journal of Pediatric Gastroenterology and Nutrition. 2013;56(6):597-601.
Not in our library10.1097/mpg.0b013e318292fa0d
115.
Lee Y-M, Kim K-S, Jacobs DR, Lee D-H. Persistent organic pollutants in adipose tissue should be considered in obesity research. Obesity Reviews. 2017;18(2):129-139.
Not in our library10.1111/obr.12481
116.
Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC, Gobourne A, Ling L, Pamer EG. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. Journal of Infectious Diseases. 2015;212(10):1656-1665.
Not in our library10.1093/infdis/jiv256
117.
Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(31):11070-11075.
Not in our library10.1073/pnas.0504978102
118.
Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-/- mice. Circulation. 2016a;133(24):2434-2446.
Not in our library10.1161/circulationaha.115.019645
119.
Gut microbiota dysbiosis contributes to the development of hypertension · 2017
No notice
120.
Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt AY, Zeller G, Sunagawa S, de Vos WM, Bork P. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science. 2016b;352(6285):586-589.
Not in our library10.1126/science.aad8852
121.
Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population · 2016
No notice
122.
Link A, Becker V, Goel A, Wex T, Malfertheiner P, Hoheisel JD. Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLOS ONE. 2012;7(8):e42933.
Not in our library10.1371/journal.pone.0042933
123.
Liu S, Da Cunha AP, Rezende RM, Cialic R, Wei Z, Bry L, Comstock LE, Gandhi R, Weiner HL. The host shapes the gut microbiota via fecal microRNA. Cell Host & Microbe. 2016;19(1):32-43.
Not in our library10.1016/j.chom.2015.12.005
124.
Llopis M, Cassard-Doulcier AM, Boschat L, Bruneau A, Cailleux F, Rabot S, Gaudin F, Berrebi D, Naveau S, Gérard P, Perlemuter G. Intestinal dysbiosis explains inter-individual differences in susceptibility to alcoholic liver disease. Journal of Hepatology. 2014;60(1):S61.
Not in our library10.1016/s0168-8278(14)60148-3
125.
Louie TJ, Louie MR, Krulicki W, Byrne B, Ward L. Home-based fecal flora infusion to arrest multiply-recurrent Clostridium difficile infection (CDI). 2008.
Not in our library
126.
Luckey D, Gomez A, Murray J, White B, Taneja V. Bugs & us: the role of the gut in autoimmunity. Indian Journal of Medical Research. 2013;138:732.
Not in our library
127.
M'Rabet L, Vos AP, Boehm G̈, Garssen J. Breast-feeding and its role in early development of the immune system in infants: consequences for health later in life. Journal of Nutrition. 2008;138(9):1782S-1790S.
Not in our library10.1093/jn/138.9.1782s
128.
Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. American Journal of Clinical Nutrition. 1999;69(5):1035s-1045s.
Not in our library10.1093/ajcn/69.5.1035s
129.
Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004;303(5664):1662-1665.
Not in our library10.1126/science.1091334
130.
Makkawi S, Camara-Lemarroy C, Metz L. Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. Neurology-Neuroimmunology Neuroinflammation. 2018;5(4):e459.
Not in our library10.1212/nxi.0000000000000459
131.
Massacand JC, Kaiser P, Ernst B, Tardivel A, Bürki K, Schneider P, Harris NL. Intestinal bacteria condition dendritic cells to promote IgA production. PLOS ONE. 2008;3(7):e2588.
Not in our library10.1371/journal.pone.0002588
132.
Mattila E, Uusitalo–Seppälä R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, Moilanen V, Salminen K, Seppälä M, Mattila PS, Anttila V–J, Arkkila P. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142(3):490-496.
Not in our library10.1053/j.gastro.2011.11.037
133.
Maudet C, Mano M, Eulalio A. MicroRNAs in the interaction between host and bacterial pathogens. FEBS Letters. 2014;588(22):4140-4147.
Not in our library10.1016/j.febslet.2014.08.002
134.
Mizuno S, Masaoka T, Naganuma M, Kishimoto T, Kitazawa M, Kurokawa S, Nakashima M, Takeshita K, Suda W, Mimura M, Hattori M, Kanai T. Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. Digestion. 2017;96(1):29-38.
Not in our library10.1159/000471919
135.
Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102-109.e6.
Not in our library10.1053/j.gastro.2015.04.001
136.
Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatric Research. 2008;64(4):418-422.
Not in our library10.1203/pdr.0b013e318181b7fa
137.
Mohan R, Koebnick C, Schildt J, Schmidt S, Mueller M, Possner M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. Journal of Clinical Microbiology. 2006;44(11):4025-4031.
Not in our library10.1128/jcm.00767-06
138.
Mukherjee S, Zheng H, Derebe MG, Callenberg KM, Partch CL, Rollins D, Propheter DC, Rizo J, Grabe M, Jiang Q-X, Hooper LV. Antibacterial membrane attack by a pore-forming intestinal C-type lectin. Nature. 2014;505(7481):103-107.
Not in our library10.1038/nature12729
139.
Nagpal R, Tsuji H, Takahashi T, Nomoto K, Kawashima K, Nagata S, Yamashiro Y. Ontogenesis of the gut microbiota composition in healthy, full-term, vaginally born and breast-fed infants over the first 3 years of life: a quantitative bird’s-eye view. Frontiers in Microbiology. 2017;8:1388.
Not in our library10.3389/fmicb.2017.01388
140.
Nishino K, Nishida A, Inoue R, Kawada Y, Ohno M, Sakai S, Inatomi O, Bamba S, Sugimoto M, Kawahara M, Naito Y, Andoh A. Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. Journal of Gastroenterology. 2018;53(1):95-106.
Not in our library10.1007/s00535-017-1384-4
141.
Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study · 2016
No notice
142.
Ouwehand A, Isolauri E, Salminen S. The role of the intestinal microflora for the development of the immune system in early childhood. European Journal of Nutrition. 2002;41:i32-i37.
Not in our library10.1007/s00394-002-1105-4
143.
Paramsothy S, Kamm M, Walsh A, Van Den Bogaerde J, Douglas Samuel RL, Connor S, Ng W, Paramsothy R, Kaakoush N. Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial. Journal of Crohn's and Colitis. 2016;10:S14.
Not in our library
144.
Paterson DL, Iredell J, Whitby M. Putting back the bugs: bacterial treatment relieves chronic diarrhoea. Medical Journal of Australia. 1994;160:232-233.
Not in our library
145.
Pepin J, Alary M-E, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clinical Infectious Diseases. 2005;40(11):1591-1597.
Not in our library10.1086/430315
146.
Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. American Journal of Gastroenterology. 2000;95:3283.
Not in our library10.1111/j.1572-0241.2000.03302.x
147.
Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. American Journal of Gastroenterology. 2014;109(11):1831-1832.
Not in our library10.1038/ajg.2014.295
148.
Podolsky DK, Lynch-Devaney K, Stow JL, Oates P, Murgue B, DeBeaumont M, Sands BE, Mahida YR. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. Journal of Biological Chemistry. 1993;268:6694-6702.
Not in our library
149.
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto J-M, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.
Not in our library10.1038/nature08821
150.
Quraishi MN, Sergeant MJ, Kay GL, Iqbal T, Constantinidou C, Chan J, Trivedi PJ, Ferguson JW, Adams DH, Pallen MJ. Probing the microbiota in PSC: the gut adherent microbiota of PSC-IBD is distinct to that of IBD and controls. Hepatology. 2014;60:264A-267A.
Not in our library10.1002/hep.27470
151.
Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annual Review of Biochemistry. 2002;71(1):635-700.
Not in our library10.1146/annurev.biochem.71.110601.135414
152.
Ramnani P, Chitarrari R, Tuohy K, Grant J, Hotchkiss S, Philp K, Campbell R, Gill C, Rowland I. In vitro fermentation and prebiotic potential of novel low molecular weight polysaccharides derived from agar and alginate seaweeds. Anaerobe. 2012;18(1):1-6.
Not in our library10.1016/j.anaerobe.2011.08.003
153.
Randal Bollinger R, Everett ML, Palestrant D, Love SD, Lin SS, Parker W. Human secretory immunoglobulin A may contribute to biofilm formation in the gut. Immunology. 2003;109(4):580-587.
Not in our library10.1046/j.1365-2567.2003.01700.x
154.
Rawls JF, Mahowald MA, Ley RE, Gordon JI. Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell. 2006;127(2):423-433.
Not in our library10.1016/j.cell.2006.08.043
155.
Ray K. Gut microbiota: filling up on fibre for a healthy gut. Nature Reviews Gastroenterology & Hepatology. 2018;15(2):67-67.
Not in our library10.1038/nrgastro.2018.2
156.
Rees CM, Hall NJ, Fleming P, Eaton S. Probiotics for the prevention of surgical necrotising enterocolitis: systematic review and meta-analysis. BMJ Paediatrics Open. 2017;1(1):e000066.
Not in our library10.1136/bmjpo-2017-000066
157.
Ringel Y, Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. Journal of Clinical Gastroenterology. 2011;45:S145-S148.
Not in our library10.1097/mcg.0b013e31822d32d3
158.
A Meta-Analysis of Probiotic Efficacy for Gastrointestinal Diseases · 2012
No notice
159.
Rokka S, Rantamäki P. Protecting probiotic bacteria by microencapsulation: challenges for industrial applications. European Food Research and Technology. 2010;231(1):1-12.
Not in our library10.1007/s00217-010-1246-2
160.
Rossen NG, Fuentes S, Boonstra K, D’Haens GR, Heilig HG, Zoetendal EG, De Vos WM, Ponsioen CY. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. Journal of Crohn's and Colitis. 2014;9(4):342-348.
Not in our library10.1093/ecco-jcc/jju023
161.
Rossen NG, Fuentes S, Van Der Spek MJ, Tijssen JG, Hartman JHA, Duflou A, Löwenberg M, Van Den Brink GR, Mathus-Vliegen EMH, De Vos WM, Zoetendal EG, D'Haens GR, Ponsioen CY. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110-118.e4.
Not in our library10.1053/j.gastro.2015.03.045
162.
Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, Shilo S, Lador D, Vila AV, Zmora N, Pevsner-Fischer M, Israeli D, Kosower N, Malka G, Wolf BC, Avnit-Sagi T, Lotan-Pompan M, Weinberger A, Halpern Z, Carmi S, Fu J, Wijmenga C, Zhernakova A, Elinav E, Segal E. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555(7695):210-215.
Not in our library10.1038/nature25973
163.
Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe. 2013;19:22-26.
Not in our library10.1016/j.anaerobe.2012.11.004
164.
Russell SL, Finlay BB. The impact of gut microbes in allergic diseases. Current Opinion in Gastroenterology. 2012;28(6):563-569.
Not in our library10.1097/mog.0b013e3283573017
165.
Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Seminars in Immunology. 2007;19(2):70-83.
Not in our library10.1016/j.smim.2007.04.002
166.
Schroeder BO, Birchenough GMH, Ståhlman M, Arike L, Johansson MEV, Hansson GC, Bäckhed F. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host & Microbe. 2018;23(1):27-40.e7.
Not in our library10.1016/j.chom.2017.11.004
167.
Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database of Systematic Reviews. 2015;12:CD008772.
Not in our library10.1002/14651858.cd008772.pub2
168.
Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiological Reviews. 2010;90(3):859-904.
Not in our library10.1152/physrev.00045.2009
169.
Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiology Reviews. 2004;28(4):405-440.
Not in our library10.1016/j.femsre.2004.01.003
170.
Sherman MP, Zaghouani H, Niklas V. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatric Research. 2014;77(1–2):127-135.
Not in our library10.1038/pr.2014.161
171.
Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clinical Gastroenterology and Hepatology. 2010;8(5):471-473.
Not in our library10.1016/j.cgh.2010.01.007
172.
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Man Lei Y, Jabri B, Alegre M-L, Chang EB, Gajewski TF. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084-1089.
Not in our library10.1126/science.aac4255
173.
Fiber and Prebiotics: Mechanisms and Health Benefits · 2013
No notice
174.
Spindelboeck W, Schulz E, Uhl B, Kashofer K, Aigelsreiter A, Zinke-Cerwenka W, Mulabecirovic A, Kump PK, Halwachs B, Gorkiewicz G, Sill H, Greinix H, Högenauer C, Neumeister P. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease. Haematologica. 2017;102(5):e210-e213.
Not in our library10.3324/haematol.2016.154351
175.
Stark PL, Lee A, Parsonage BD. Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study. Infection and Immunity. 1982;35(3):895-899.
Not in our library10.1128/iai.35.3.895-899.1982
176.
Stecher B, Hardt W-D. The role of microbiota in infectious disease. Trends in Microbiology. 2008;16(3):107-114.
Not in our library10.1016/j.tim.2007.12.008
177.
Stratiki Z, Costalos C, Sevastiadou S, Kastanidou O, Skouroliakou M, Giakoumatou A, Petrohilou V. The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants. Early Human Development. 2007;83(9):575-579.
Not in our library10.1016/j.earlhumdev.2006.12.002
178.
Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, Singh N, Damman CJ, Hager KR, Nielson H, Miller SI. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflammatory Bowel Diseases. 2015;21(3):556-563.
Not in our library10.1097/mib.0000000000000307
179.
Suzuki K, Meek B, Doi Y, Muramatsu M, Chiba T, Honjo T, Fagarasan S. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(7):1981-1986.
Not in our library10.1073/pnas.0307317101
180.
Tabibian JH, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. BioMed Research International. 2013;2013(4):389537.
Not in our library10.1155/2013/389537
181.
Mucin glycan foraging in the human gut microbiome · 2015
No notice
182.
Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, Inatomi O, Bamba S, Andoh A, Sugimoto M. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn's disease. Digestion. 2016;93(1):59-65.
Not in our library10.1159/000441768
183.
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805-820.
Not in our library10.1016/j.cell.2010.01.022
184.
Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. New England Journal of Medicine. 2013;368(17):1575-1584.
Not in our library10.1056/nejmoa1109400
185.
Tannock GW, Munro K, Harmsen HJM, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Applied and Environmental Microbiology. 2000;66(6):2578-2588.
Not in our library10.1128/aem.66.6.2578-2588.2000
186.
Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, Huffnagle GB, Li JZ, Young VB. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nature Communications. 2014;5(1):3114.
Not in our library10.1038/ncomms4114
187.
Introduction to the human gut microbiota · 2017
No notice
188.
Tian H, Ding C, Gong J, Wei Y, McFarland LV, Li N. Freeze-dried, capsulized fecal microbiota transplantation for relapsing Clostridium difficile infection. Journal of Clinical Gastroenterology. 2015;49:537-538.
Not in our library10.1097/mcg.0000000000000330
189.
Tian H, Ge X, Nie Y, Yang L, Ding C, McFarland LV, Zhang X, Chen Q, Gong J, Li N, Green J. Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. PLOS ONE. 2017;12(2):e0171308.
Not in our library10.1371/journal.pone.0171308
190.
Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. Journal of Clinical Investigation. 2011;121(6):2126-2132.
Not in our library10.1172/jci58109
191.
Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242-249.
Not in our library10.1038/nature11552
192.
Trøseid M. Gut microbiota and acute coronary syndromes: ready for use in the emergency room? European Heart Journal. 2017;38(11):825-827.
Not in our library10.1093/eurheartj/ehx005
193.
Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480-484.
Not in our library10.1038/nature07540
194.
Udayappan SD, Hartstra AV, Dallinga-Thie GM, Nieuwdorp M. Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus. Clinical & Experimental Immunology. 2014;177(1):24-29.
Not in our library10.1111/cei.12293
195.
Umu ÖCO, Rudi K, Diep DB. Modulation of the gut microbiota by prebiotic fibres and bacteriocins'. Microbial Ecology in Health and Disease. 2017;28(1):1348886.
Not in our library10.1080/16512235.2017.1348886
196.
Uygun A, Ozturk K, Demirci H, Oger C, Avci IY, Turker T, Gulsen M. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. Medicine. 2017;96(16):e6479.
Not in our library10.1097/md.0000000000006479
197.
Van Den Abbeele P, Taminiau B, Pinheiro I, Duysburgh C, Jacobs H, Pijls L, Marzorati M. Arabinoxylo-oligosaccharides and inulin impact inter-individual variation on microbial metabolism and composition, which immunomodulates human cells. Journal of Agricultural and Food Chemistry. 2018;66(5):1121-1130.
Not in our library10.1021/acs.jafc.7b04611
198.
Van Nood E, Dijkgraaf MG, Nieuwdorp M, Fuentes S, Zoetendal EG, De Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ. Duodenal infusion of feces for recurrent Clostridium difficile. New England Journal of Medicine. 2013;368(5):407-415.
Not in our library10.1056/nejmoa1205037
199.
Vandenplas Y, Zakharova I, Dmitrieva Y. Oligosaccharides in infant formula: more evidence to validate the role of prebiotics. British Journal of Nutrition. 2015;113(9):1339-1344.
Not in our library10.1017/s0007114515000823
200.
Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. Journal of Crohn's and Colitis. 2015;10(4):387-394.
Not in our library10.1093/ecco-jcc/jjv203
201.
Gut Microbiota Profiling: Metabolomics Based Approach to Unravel Compounds Affecting Human Health · 2016
No notice
202.
Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, Van Nood E, Holleman F, Knaapen M, Romijn JA, Soeters MR, Blaak EE, Dallinga-Thie GM, Reijnders D, Ackermans MT, Serlie MJ, Knop FK, Holst JJ, Van der Ley C, Kema IP, Zoetendal EG, De Vos WM, Hoekstra JBL, Stroes ES, Groen AK, Nieuwdorp M. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. Journal of Hepatology. 2014;60(4):824-831.
Not in our library10.1016/j.jhep.2013.11.034
203.
Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga–Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JET, Bloks VW, Groen AK, Heilig HGHJ, Zoetendal EG, Stroes ES, De Vos WM, Hoekstra JBL, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-916.e7.
Not in our library10.1053/j.gastro.2012.06.031
204.
Wahlström A, Sayin SI, Marschall H-U, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metabolism. 2016;24(1):41-50.
Not in our library10.1016/j.cmet.2016.05.005
205.
Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley GE, Parkhill J, Flint HJ. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME Journal. 2011;5(2):220-230.
Not in our library10.1038/ismej.2010.118
206.
Walker WA, Iyengar RS. Breast milk, microbiota, and intestinal immune homeostasis. Pediatric Research. 2014;77(1–2):220-228.
Not in our library10.1038/pr.2014.160
207.
Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life · 2017
No notice
208.
Watson AJM, Hall LJ. Regulation of host gene expression by gut microbiota. Gastroenterology. 2013;144(4):841-844.
Not in our library10.1053/j.gastro.2013.02.028
209.
Weber JA, Baxter DH, Zhang S, Huang DY, How Huang K, Jen Lee M, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clinical Chemistry. 2010;56(11):1733-1741.
Not in our library10.1373/clinchem.2010.147405
210.
Wen L, Duffy A. Factors influencing the gut microbiota, inflammation, and type 2 diabetes. Journal of Nutrition. 2017;147(7):1468S-1475S.
Not in our library10.3945/jn.116.240754
211.
Wettstein A, Borody TJ, Leis S, Chongnan J, Torres M, Hills LA. Fecal bacteriotherapy-an effective treatment for relapsing symptomatic Clostridium difficile infection. Gut. 2007;56:A303.
Not in our library
212.
Wilcox GM. Early experience with a fecal bacteriotherapy (FB) program for recurrent and C-difficile infection (CDI). Gastroenterology. 2011;140(5):S-361.
Not in our library10.1016/s0016-5085(11)61476-5
213.
Wiley NC, Dinan TG, Ross RP, Stanton C, Clarke G, Cryan JF. The microbiota-gut-brain axis as a key regulator of neural function and the stress response: implications for human and animal health. Journal of Animal Science. 2017;95:3225-3246.
Not in our library10.2527/jas.2016.1256
214.
Windey K, De Preter V, Verbeke K. Relevance of protein fermentation to gut health. Molecular Nutrition & Food Research. 2012;56(1):184-196.
Not in our library10.1002/mnfr.201100542
215.
Wong SH, Zhao L, Zhang X, Nakatsu G, Han J, Xu W, Xiao X, Kwong TNY, Tsoi H, Wu WKK, Zeng B, Chan FKL, Sung JJY, Wei H, Yu J. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology. 2017;153(6):1621-1633.e6.
Not in our library10.1053/j.gastro.2017.08.022
216.
Wu Y, Zhang Q, Ren Y, Ruan Z, Norata GD. Effect of probiotic Lactobacillus on lipid profile: a systematic review and meta-analysis of randomized, controlled trials. PLOS ONE. 2017;12(6):e0178868.
Not in our library10.1371/journal.pone.0178868
217.
Xie HY, Feng D, Wei DM, Mei L, Chen H, Wang X, Fang F. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database of Systematic Reviews. 2017;11:CD010496.
Not in our library10.1002/14651858.cd010496.pub2
218.
Xue X, Feng T, Yao S, Wolf KJ, Liu C-G, Liu X, Elson CO, Cong Y. Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40. Journal of Immunology. 2011;187(11):5879-5886.
Not in our library10.4049/jimmunol.1100535
219.
Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137(2):588-597.
Not in our library10.1053/j.gastro.2009.04.046
220.
Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, Gordon JI. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222-227.
Not in our library10.1038/nature11053
221.
Yoshioka H, Iseki K-I, Fujita K. Development and differences of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. Pediatrics. 1983;72:317-321.
Not in our library
222.
Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014a;312(17):1772-1778.
Not in our library10.1001/jama.2014.13875
223.
Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, Hohmann EL. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clinical Infectious Diseases. 2014b;58(11):1515-1522.
Not in our library10.1093/cid/ciu135
224.
Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clinical Infectious Diseases. 2007;45(3):302-307.
Not in our library10.1086/519265
225.
Zarepour M, Bhullar K, Montero M, Ma C, Huang T, Velcich A, Xia L, Vallance BA, Bäumler AJ. The mucin Muc2 limits pathogen burdens and epithelial barrier dysfunction during Salmonella enterica serovar Typhimurium colitis. Infection and Immunity. 2013;81(10):3672-3683.
Not in our library10.1128/iai.00854-13
226.
Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? American Journal of Gastroenterology. 2012;107(11):1755.
Not in our library10.1038/ajg.2012.251
227.
Zhang Q, Wu Y, Fei X. Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Medicina. 2016;52(1):28-34.
Not in our library10.1016/j.medici.2015.11.008
228.
Zhao S, Liu W, Wang J, Shi J, Sun Y, Wang W, Ning G, Liu R, Hong J. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. Journal of Molecular Endocrinology. 2017;58(1):1-14.
Not in our library10.1530/jme-16-0054
229.
The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice · 2019
No notice
230.
Zhou K. Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies. Journal of Functional Foods. 2017;33:194-201.
Not in our library10.1016/j.jff.2017.03.045

Cited by papers we hold 18

Bacterial Biofilm in Chronic Wounds and Possible Therapeutic Approaches · 2024
No notice
Elucidating the role of diet in maintaining gut health to reduce the risk of obesity, cardiovascular and other age-related inflammatory diseases: recent challenges and future recommendations · 2024
No notice
A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation · 2024
No notice
Gut Microbiome–Brain Alliance: A Landscape View into Mental and Gastrointestinal Health and Disorders · 2023
No notice
Role of gut microbiota in infectious and inflammatory diseases · 2023
No notice
Mechanisms and regulation of defensins in host defense · 2023
No notice
Let’s review the gut microbiota in systemic lupus erythematosus · 2022
Not checked
Investigation of the Ecological Link between Recurrent Microbial Human Gut Communities and Physical Activity · 2022
Not checked
Treatment With Multi-Species Probiotics Changes the Functions, Not the Composition of Gut Microbiota in Postmenopausal Women With Obesity: A Randomized, Double-Blind, Placebo-Controlled Study · 2022
Not checked
The Connection Between Physical Exercise and Gut Microbiota: Implications for Competitive Sports Athletes · 2022
No notice
The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review · 2022
No notice
Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases · 2022
No notice
A Review: Composition of Neonatal Meconium Microbiota and Its Role for Potential Probiotic · 2021
Not checked
Biofilm-Innate Immune Interface: Contribution to Chronic Wound Formation · 2021
No notice
The Effects of Intermittent Fasting on Brain and Cognitive Function · 2021
No notice
Investigating causality with fecal microbiota transplantation in rodents: applications, recommendations and pitfalls · 2021
No notice
The effects of different dietary fiber pectin structures on the gastrointestinal immune barrier: impact via gut microbiota and direct effects on immune cells · 2020
No notice
The Role of the Microbiome in Driving RA-Related Autoimmunity · 2020
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.